Publicaciones en las que colabora con JULIA ORIGÜEN SABATER (22)

2024

  1. Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 2, pp. 313-324

  2. Risk factors for poor outcome in adult patients with respiratory syncytial virus infection evaluated at the emergency department

    Journal of Medical Virology, Vol. 96, Núm. 10

2023

  1. Evaluation of the effectiveness and safety of oral vancomycin versus placebo in the prevention of recurrence of Clostridioides difficile infection in patients under systemic antibiotic therapy: a phase III, randomised, double-blind clinical trial

    BMJ open, Vol. 13, Núm. 9, pp. e072121

2022

  1. Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19

    International Journal of Infectious Diseases, Vol. 117, pp. 56-64

2021

  1. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study

    International Journal of Infectious Diseases, Vol. 105, pp. 487-494

  2. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study

    International Journal of Infectious Diseases, Vol. 105, pp. 319-325

  3. Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients: Results from a spanish multicenter cohort

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 5

  4. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study

    Journal of Medical Virology, Vol. 93, Núm. 2, pp. 831-842

2020

  1. Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients—Results of a Spanish multicenter cohort

    American Journal of Transplantation, Vol. 20, Núm. 2, pp. 451-462

2019

  1. Toxin B PCR amplification cycle threshold adds little to clinical variables for predicting outcomes in clostridium difficile infection: A retrospective cohort study

    Journal of Clinical Microbiology, Vol. 57, Núm. 2

2018

  1. Características demográficas y de parentesco de los donantes vivos de riñón.

    XXII Encuentro Internacional de Investigación en Cuidados

  2. Comparison of the clinical course of Clostridium difficile infection in glutamate dehydrogenase-positive toxin-negative patients diagnosed by PCR to those with a positive toxin test

    Clinical Microbiology and Infection, Vol. 24, Núm. 4, pp. 414-421

  3. Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study

    Transplant International, Vol. 31, Núm. 2, pp. 187-197

  4. Impact on mortality of adherence to evidence-based interventions in patients with catheter-related bloodstream infection due to methicillin-sensitive Staphylococcus aureus

    Infectious Diseases, Vol. 50, Núm. 11-12, pp. 837-846

  5. Post-transplant hypocomplementemia: A novel marker of cardiovascular risk in kidney transplant recipients?

    Atherosclerosis, Vol. 269, pp. 204-210

  6. T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: A prospective pilot study

    Journal of Antimicrobial Chemotherapy, Vol. 73, pp. iv6-iv12

  7. T2MR contributes to the very early diagnosis of complicated candidaemia. A prospective study

    Journal of Antimicrobial Chemotherapy, Vol. 73, pp. iv13-iv19

2017

  1. Serum sCD30: A promising biomarker for predicting the risk of bacterial infection after kidney transplantation

    Transplant Infectious Disease, Vol. 19, Núm. 2

2016

  1. Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options

    Transplant Infectious Disease, Vol. 18, Núm. 4, pp. 575-584

  2. Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial

    American Journal of Transplantation, Vol. 16, Núm. 10, pp. 2943-2953